Moderate riskFDA DrugClass II

Harbin Jixianglong semaglutide recalled for incomplete manufacturing validation

The FDA is recalling semaglutide powder distributed by Harbin Jixianglong Biotech for compounding use only. The manufacturer did not complete required manufacturing process and bacterial endotoxin testing before shipping the product. This was a manufacturing oversight, not a confirmed safety incident.

From the FDA notice · Read the official notice ↗

What to do

  1. If you use compounded semaglutide, contact your pharmacy or prescriber to confirm whether your medication is affected.
  2. Do not stop taking semaglutide without talking to your doctor.
  3. Your pharmacy will advise you on next steps if your medication is part of this recall.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China.
Sold in
Nationwide
Made for
All ages (0 months and older)

This recall covers 2 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
North Of Baoan Road, East Of Changqing Street, Hulan District, Haerbin, N/A, China
Classification
Class II
Recall number
D-0380-2026

In the FDA's words

Description
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China. CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution Batch # CP-030-20250911, Mfg Date: Sep. 25th, 2025, Retest Date: Sep. 24th, 2027. Distribution: Nationwide within the United States Affected quantity: N/A
Hazard
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

2 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

OtherDrugsSold nationwideMore from FDA Drug